Hikma Launches US Vascepa Rival As Amarin Appeal Denied
Initially Offering Limited Quantities As Firm Scales Up Production
Hikma has launched its US rival to Vascepa, after the US Court of Appeals for the Federal Circuit refused a request by Amarin for an “en banc” rehearing of key litigation.
